Shades of the Vioxx Case for Another Drug
Interesting dilemma. Right now, they need a prospective study to determine the risks of Bextra – however, it will be several years before the results are in. So, what to do in the meantime? I probably wouldn’t prescribe this in those with cardiac risk factors – we may be going down the same Vioxx path.
Shades of the Vioxx Case for Another Drug
Real physician voices, twice a week
Free, and one click to unsubscribe.
Keep reading
The Podcast
Latest episodes
Most popular
Hidden fees in employer health plans are about to come out
Bringing a newborn home? What hospitals don’t tell new parents
Is your clinical AI tool safe? 4 questions to ask first
Physician pay won’t budge for one doctor. Negotiate as a group.
Shy doctors can lead: imposter syndrome and the path to physician leadership
Clinical trials answer drug questions. Health questions need other tools.
Fired for seeing her own patients: moral injury and life after medicine
